May 03, 2013
The 11th Circuit refused Thursday to let a Florida hospital appeal in hopes of winning certification of an $867 million antitrust class action accusing Astellas Pharma Inc. of improperly requiring use of its Adenoscan drug with patented cardiac tests, but the provider intends to soldier on alone.
January 14, 2013
A Florida federal judge on Monday again refused to grant class certification of an $867 million antitrust class action accusing Astellas Pharma Inc. of improperly requiring use of its Adenoscan drug with patented cardiac tests, saying there was no legal or factual reason to reconsider the denial.
October 10, 2012
A Florida hospital on Tuesday again requested certification of an $867 million antitrust class action accusing Astellas Pharma Inc. of improperly requiring use of its Adenoscan drug with patented cardiac tests, saying an earlier denial misread the U.S. Supreme Court's ruling in Illinois Brick Co. v. Illinois.
September 26, 2012
A federal judge ruled Monday that a Florida hospital didn't have standing to file an $867 million antitrust class action accusing Astellas Pharma Inc. of abusing a patent monopoly to force health care providers to use only an Astellas-brand cardiac testing drug.
July 26, 2011
A Florida federal judge on Monday refused to dismiss Lakeland Regional Medical Center Inc.'s antitrust class action against affiliates of Astellas Pharma Inc. over patented cardiac stress test procedures, saying Lakeland's complaint cleared several hurdles including U.S. Supreme Court precedent.
September 14, 2010
A Florida hospital has filed a putative class action against U.S.-based affiliates of Astellas Pharma Inc., alleging the Japanese pharmaceutical company’s promotion of its patented cardiac stress test procedures has violated antitrust laws.